Table 3 Ongoing clinical trials of DC vaccines in patients with AML/MDS, melanoma, glioma/glioblastoma, lung cancers, prostate cancer and lymphoma
From: Research progress on dendritic cell vaccines in cancer immunotherapy
Type of cancer | NCT ID | Stage of disease | Phase | Source of DC | DC methods | Primary outcomes |
|---|---|---|---|---|---|---|
AML/MDS | NCT00965224 | AML CR with high risk of relapse or previous relapse | II | Autologous DCs | WT1 mRNA-electroporated autologous DCs | Immunogenicity of DC vaccines |
NCT01096602 | AML | II | Autologous DCs | DC AML vaccine combined with PD-1 blockade | Toxicity | |
NCT01146262 | AML first or second CR | I/II | Autologous DCs | Leukemic apoptotic corpse autologous pulsed DCs | Adverse events | |
NCT01686334 | Relapsed adult non-M3 AML | II | Autologous DCs | WT1 mRNA-electroporated DCs | OS | |
NCT03059485 | AML at initial diagnosis or first relapse | II | Autologous DCs | DC/AML cell vaccine | PFS | |
NCT03291444 | Relapsed/refractory leukemia/MDS | I | Autologous DCs | Eps8 peptide-specific DCs | Adverse events | |
NCT03679650 | AML with allogeneic transplantation | I | Autologous DCs | DC/AML cell fusion vaccine | Fold-increase in AML-specific T cells in the peripheral blood and bone marrow | |
NCT03697707 | AML in remission with persistent MRD | II | Allogeneic DCs | 25E6 cells/vaccination of DCP-001 | MRD | |
Melanoma | NCT00004025 | Melanoma (skin) | I/II | Autologous DCs | Autologous dendritic cells transduced with adenoviruses encoding the MART-1 and gp100 melanoma antigens with or without interleukin-2 | Safety, dose-limiting toxicity, and maximum tolerated dose |
NCT00017355 | Melanoma (skin) | I | Autologous DCs | Autologous DC vaccines made from a patient’s white blood cells mixed with tumor antigens | Safety and tolerability and longevity of melanoma-specific immunity | |
NCT00085397 | Melanoma (skin) | II | Autologous DCs | Autologous DCs pulsed with gp100 antigen and autologous DCs fused with autologous tumor cells | Immune response | |
NCT00126685 | Melanoma (skin) | I/II | Autologous DCs | Autologous dendritic cells (DC) transfected with autologous polymerase chain reaction-amplified tumor RNA | Safety, immunogenicity, objective tumor response, time to disease progression, progression-free interval, OS | |
NCT00338377 | Melanoma | II | Autologous DCs | Lymphodepletion plus adoptive cell transfer with or without DC immunization in patients with metastatic melanoma | Objective response (OR), longitudinal immune response, overall response rate (ORR) | |
NCT01082198 | Melanoma (skin) | I/II | Autologous DCs | Autologous dendritic cells pulsed with tumor antigen peptides | Immune response, disease-free survival, OS, AEs | |
NCT01331915 | Melanoma | I/II | Autologous DCs | Proteinic vector targeting DCs coupled to a melanoma antigen, | Safety and toxicity, immune response | |
NCT01456104 | Melanoma | I | Autologous DCs | Autologous Langerhans-type DCs electroporated with mRNA encoding a tumor-associated antigen | Safety, toxicity | |
NCT01753089 | Melanoma | I | Autologous DCs | DC activating scaffold incorporating autologous melanoma cell lysate (WDVAX) | Feasibility, safety and biologic activity | |
NCT01946373 | Melanoma | II | Autologous DCs | Adoptive T cell transfer with or without DC vaccination | Safety | |
NCT01973322 | Malignant melanoma of skin stage III/IV | II | Autologous DCs | Autologous tumor lysates | Safety, tolerability and feasibility, immune related disease control rate, immunologic efficacy | |
NCT01983748 | Uveal melanoma | III | Autologous DCs | Adjuvant vaccination with tumor RNA-loaded autologous DCs | Overall survival | |
NCT02301611 | Melanoma | II | Autologous DCs | Vaccine containing autologous tumor lysate (TL) + yeast cell wall particles (YCWPs) + DCs | Disease-free survival assessment | |
NCT02334735 | Melanoma | II | Autologous DCs | Mature DC as an adjuvant for NY-ESO-1 and melan-A/MART-1 peptide vaccination | Humoral immune response, cytokine secretion | |
NCT02993315 | Melanoma (skin) | III | Autologous DCs | Natural DCs pulsed with synthetic peptides | Recurrence-free survival rate | |
NCT03092453 | Advanced melanoma | I | Autologous DCs | Mature DC vaccination against mutated antigens in patients with advanced melanoma | Immune response of specific T cells | |
NCT03325101 | Stage IIIA/B cutaneous melanoma | I/II | Autologous DCs | Autologous DCs therapy delivered intratumorally after cryoablation in combination with pembrolizumab | Tumor response rate | |
NCT04093323 | Refractory melanoma | II | Autologous DCs | Type-1 polarized DC vaccine in combination with tumor-selective chemokine modulation | Objective response rate (ORR) | |
NCT04335890 | Uveal metastatic melanoma | I | Autologous DCs | Mature DCs loaded with autologous tumor-RNA + RNA encoding defined antigens and driver mutations | Safety, tolerability, dose-limiting toxicities, maximum tolerated dose | |
Glioma/Glioblastoma | NCT01204684 | Glioma, anaplastic astrocytoma, anaplastic astro oligodendroglioma, glioblastoma | II | Autologous DCs | Autologous tumor lysate-pulsed DC vaccination | Time to tumor progression and overall survival |
NCT01291420 | Glioblastoma, renal cell carcinoma, sarcomas, breast cancers, malignant mesothelioma, colorectal tumors | I/II | Autologous DCs | Intradermal vaccination with autologous RNA-modified DCs-engineered to express the WT1 protein | Immunogenicity of intradermal DC vaccination | |
NCT01567202 | Glioma, glioblastoma multiforme | II | Autologous DCs | DCs loaded with glioma stem-like cell-associated antigens against brain glioblastoma multiforme | ORR, PFS, OS | |
NCT01808820 | Malignant glioma, glioblastoma multiforme, anaplastic astrocytoma, high grade glioma | I | Autologous DCs | Patients derived DC vaccine | Safety and toxicity, AEs | |
NCT01957956 | Giant cell glioblastoma, glioblastoma, gliosarcoma | I | Autologous DCs | Malignant glioma tumor lysate-pulsed autologous DC vaccine | Safety and toxicity | |
NCT02366728 | Glioblastoma, grade IV astrocytoma, giant cell glioblastoma, glioblastoma multiforme | II | Autologous DCs | Human CMV pp65-LAMP mRNA-pulsed autologous DCs | Median OS, median PFS | |
NCT02465268 | Glioblastoma multiforme, malignant glioma, grade IV astrocytoma | II | Autologous DCs | pp65-shLAMP DCs with GM-CSF | Median OS, median PFS | |
NCT02771301 | Glioma | N/A | Autologous DCs | IDH1R132H-DC vaccine specifically targeting the IDH1R132H mutation | Safety and efficacy | |
NCT02772094 | Glioblastoma multiforme, glioblastoma | II | Autologous DCs | Autologous DCs loaded with irradiated autologous tumor cells | OS, AEs | |
NCT03360708 | Giant cell glioblastoma, recurrent glioblastoma, recurrent gliosarcoma | I | Autologous DCs | Malignant glioma tumor lysate-pulsed autologous DC vaccine | Safety and toxicity | |
NCT03395587 | Glioblastoma | II | Autologous DCs | Tumor lysate-loaded autologous mature DC vaccine | OS, PFS, AEs | |
NCT04201873 | Recurrent glioblastoma | I | Autologous DCs | Autologous tumor lysate-pulsed DC vaccine | AEs, PFS, OS | |
NCT04523688 | Glioblastoma | II | Autologous DCs | Autologous DC vaccine loaded with autologous tumor homogenate | AEs, OS | |
NCT04552886 | Glioblastoma | I | Autologous DCs | TH-1 personalized DC vaccine | Safety and toxicity, Aes | |
NCT04963413 | Glioblastoma | I | Autologous DCs | Autologous DCs derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65-flLAMP plus GM-CSF | Proportion of patients for whom CMV pp65 RNA-pulsed DC vaccines can be generated | |
Lung Cancers | NCT04082182 | Metastatic NSCLC | I | Autologous DCs | Intravenous infusion or intradermal injection of MIDRIX4-LUNG DCs, a tetravalent autologous DC vaccine | Toxicity, safety and tolerability, maximal tolerated dose |
NCT04487756 | Extensive-stage SCLC | I/II | Autologous DCs | Intradermal injection autologous DC vaccine | PFS, AEs and SAEs (safety) | |
NCT04078269 | NSCLC | I | Autologous DCs | Novel autologous neoantigen-targeted DC vaccine, MIDRIXNEO-LUNG | Safety and tolerability, toxicity, maximum tolerated and/or feasible dose | |
NCT03371485 | NSCLC in the advanced and adjuvant settings | I | Allogeneic DCs | Intradermal injection of the allogeneic DC vaccine AST-VAC2 specifically targeting the hTERT protein | AEs | |
NCT03546361 | AJCC v8 stage IV NSCLC | I | Autologous DCs | Autologous adenovirus CCL21gen-modified DC vaccine | Maximum tolerated dose (MTD)/maximum administered dose (MAD), ORR | |
NCT03871205 | NSCLC, SCLC | I | Autologous DCs | Personalized autologous neoantigen-loaded DC vaccines | AEs (safety), immunogenicity of neoantigen-primed DC vaccines | |
NCT02140996 | Epithelial cancers of the lung, breast, ovary, prostate and colon | I | Adenoviral vector vaccine | Ad-sig-hMUC-1/ecdCD40L, adenoviral vector encoding a fusion protein vector vaccine | Safety and tolerability, immunologically active dose level | |
NCT03406715 | Relapsed SCLC | II | Autologous DCs | Vaccine inclduing autologous DCs with p53 gene insertion (Ad.p53-DC) | Disease control rate (DCR) | |
Prostate Cancer | NCT00005992 | Prostate cancer | I | Autologous DCs | Recombinant prostate-specific membrane antigen (rPSMA)-pulsed autologous DCs (CaPVax) | Safety (AEs) |
NCT01197625 | Prostate cancer | I/II | Autologous DCs | Autologous DCs loaded with mRNA from primary prostate cancer tissue, hTERT and survivin | Time to treatment failure defined by two different measurements of PSA levels > 0.5 µg/L with a minimum interval of 4 weeks in patients receiving treatment | |
NCT02140996 | Epithelial cancers of the lung, breast, ovary, prostate and colon | I | Adenoviral vector vaccine | Ad-sig-hMUC-1/ecdCD40L, adenoviral vector encoding a fusion protein vector vaccine | Safety and tolerability, immunologically active dose level | |
NCT02362451 | Prostate cancer | II | Autologous DCs | Multiepitope TARP peptide autologous DC vaccine | Difference in rate of PSA change before and after treatment | |
NCT02362464 | Prostate cancer | II | Autologous DCs | A multiepitope TARP peptide autologous DC vaccine | Safety (AEs) | |
Lymphoma | NCT01976585 | Low-grade B cell lymphoma | I/II | Autologous DCs | Intratumoral injection of rhuFlt3L/CDX-301, Poly-ICLC, and tumor-antigen loaded DCs | Response rate |
NCT03035331 | Non-Hodgkin lymphoma | I/II | Autologous DCs | Intratumoral injection of autologous DCs into the cryoablated tumors | Maximum tolerated dose (MTD) proportion of complete responses at maximum tolerated dose (MTD) | |
NCT03789097 | Non-Hodgkin lymphoma, metastatic breast cancer, and head and neck squamous cell carcinoma | I/II | Flt3L/CDX-301, poly-ICLC | In situ vaccination with Flt3L, radiation, and poly-ICLC | Dose limiting toxicity (DLT) | |
NCT00935597 | Non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, chronic lymphocytic leukemia | I | Autologous DCs | Host DC infusion after allo-HSCT | Incidence of severe graft versus host disease (GVHD) |